Company intelligence / Profile preview

Davanzia

Dublin, Ireland

Ownership: Private
Development stage: Other

Overview

Davanzia was a private biopharmaceutical company focused on the development of novel therapies for rare and orphan diseases. The company's primary focus was on advancing treatments for endocrine and metabolic disorders, specifically targeting conditions like acromegaly. Davanzia was notably involved in the development of oral formulations for somatostatin analogs, aiming to provide more patient-friendly alternatives to injectable therapies. The company was eventually acquired by Amryt Pharma, which integrated Davanzia's assets into its rare disease portfolio to strengthen its position in the global orphan drug market.

Therapeutic areas: OncologyEndocrinology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Davanzia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Davanzia.

Explore the full profile